Pharmaceutical / Drug Definition :
Inhibits adenylate cyclase, which regulates release of pain neurotransmitters (acetylcholine, dopamine, substance P, and gamma-aminobutyric acid). Also stimulates mu and kappa opioid receptors, altering perception of and emotional response to pain.
In the United States, Levorphanol Tartrate is regulated by the U.S. Food and Drug Administration (FDA). FDA has specific requirements regarding the registration and listing of Levorphanol Tartrate.
FDA Label Requirements and Exceptions
FDA Import Information
Levorphanol Tartrate (Levorphanol Tartrate Entry Refusal)
General U.S. Food and Drug Administration Guidelines for:
- Manufacturers Levorphanol Tartrate (Levorphanol Tartrate Suppliers)
- Processors Levorphanol Tartrate
- Repackers Levorphanol Tartrate
- Relabelers Levorphanol Tartrate
- Exporters Levorphanol Tartrate
- Importers Levorphanol Tartrate
For more information about Levorphanol Tartrate, simply click below:
U.S. FDA Regulations:
U.S. FDA Regulation: 21 C.F.R. Part 207
Registrar Corp assists businesses with U.S. FDA compliance. Certificates of Registration issued by Registrar Corp provide confirmation to industry that you are fulfilling U.S. FDA registration requirements. U.S. FDA does not issue or recognize Certificates of Registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.